UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification Number) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On December 19, 2019, Rite Aid Corporation (the “Company”) reported its financial position and results of operations as of and for the thirteen and thirty-nine week periods ended November 30, 2019. The press release includes the non-GAAP financial measures, “Adjusted EBITDA,” “Adjusted Net Income (Loss)” and “Adjusted Net Income (Loss) per Diluted Share.” The Company uses these non-GAAP measures in assessing its performance in addition to net income, the most directly comparable GAAP financial measure. Reconciliations of Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share to net income and net income (loss) per diluted share, the most directly comparable GAAP financial measures, are included in the press release, which is furnished as Exhibit 99.1 hereto.
The Company believes Adjusted EBITDA serves as an appropriate measure in evaluating the performance of its business and helps its investors better compare the Company’s operating performance with its competitors. The Company defines Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt retirements, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, a non-recurring litigation settlement, severance and costs related to facility closures and gain or loss on sale of assets). The current calculation of Adjusted EBITDA reflects a modification made in the second quarter of fiscal 2019 to eliminate the add back of revenue deferrals related to our customer loyalty program and to present amounts previously included within other as separate reconciling items. The Company references this non-GAAP financial measure frequently in its decision-making because it provides supplemental information that facilitates internal comparisons to historical periods and external comparisons to competitors. In addition, incentive compensation is based in part on Adjusted EBITDA and the Company bases certain of its forward-looking estimates and budgets on Adjusted EBITDA.
The Company defines Adjusted Net Income (Loss) as net income (loss) excluding amortization expense, merger and acquisition-related costs, a non-recurring litigation settlement, gains or losses on debt retirements, LIFO adjustments, goodwill and intangible asset impairment charges and the WBA merger termination fee. The current calculations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share reflect a modification made in the second quarter of fiscal 2019 to add back all amortization expenses rather than the amortization of EnvisionRx intangible assets only. The Company calculates Adjusted Net Income (Loss) per Diluted Share using the Company’s above-referenced definition of Adjusted Net Income (Loss). The Company believes Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate measures to be used in evaluating the performance of its business and help its investors better compare the Company’s operating performance over multiple periods.
In addition, the add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid’s results as if the company was on a FIFO inventory basis.
Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share should not be considered in isolation from, and are not intended to represent alternative measures of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. The Company’s definitions of Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share may not be comparable to similarly titled measurements reported by other companies or similar terms in the Company’s debt facilities.
In addition, a copy of the Company’s Earnings Release Supplement for the third quarter of fiscal 2020 is being furnished as Exhibit 99.2 to this Form 8-K.
The information (including Exhibits 99.1 and 99.2) being furnished pursuant to this “Item 2.02. Results of Operations and Financial Condition” shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 | Press Release, dated December 19, 2019. |
99.2 | Third Quarter Fiscal 2020 Supplemental Information. |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RITE AID CORPORATION | ||
Dated: December 19, 2019 | By: | /s/ James J. Comitale |
Name: James J. Comitale | ||
Title: Executive Vice President, General Counsel & Secretary |
Exhibit 99.1
Press Release
For Further Information Contact:
INVESTORS: | MEDIA: |
Byron Purcell | Christopher Savarese |
(717) 975-5809 | (717) 975-5718 |
Or investor@riteaid.com |
FOR IMMEDIATE RELEASE
Rite Aid Corporation Reports Fiscal 2020 Third Quarter Results
· | Third Quarter Net Income from Continuing Operations of $52.3 Million or $0.98 Per Share, Compared to the Prior Year Third Quarter Net Loss of $17.3 Million or $0.33 Per Share |
· | Third Quarter Adjusted Net Income from Continuing Operations of $29.1 Million or $0.54 Per Share, Compared to the Prior Year Third Quarter Adjusted Net Income of $14.7 Million or $0.28 Per Share |
· | Third Quarter Adjusted EBITDA from Continuing Operations of $158.1 Million, Compared to the Prior Year Third Quarter Adjusted EBITDA of $142.8 Million |
o | Improved Adjusted EBITDA in both the Retail Pharmacy and Pharmacy Services Segments |
· | Achieved Growth in Both Same Store Front-End Sales (Excluding Cigarettes and Tobacco Products) and Same Store Prescription Volume |
CAMP HILL, Pa. (Dec. 19, 2019) - Rite Aid Corporation (NYSE: RAD) today reported operating results for its third fiscal quarter ended November 30, 2019.
For the third quarter, the company reported net income from continuing operations of $52.3 million, or $0.98 per share, Adjusted net income from continuing operations of $29.1 million, or $0.54 per share, and Adjusted EBITDA from continuing operations of $158.1 million, or 2.9 percent of revenues.
“Our team delivered a strong quarter that provides us
with momentum as we prepare to roll out our long-term strategy and position Rite Aid Corporation as an innovative leader in our
industry,” said Rite Aid Corporation CEO Heyward Donigan. “Adjusted EBITDA grew in our retail business due to tight
expense control and prescription count growth in our retail pharmacies, which benefited from solid growth in immunizations. At
the same time, we saw improved pharmacy network management at EnvisionRxOptions.
“While we are pleased with these results, we have important work ahead of us to put our company on a path to long-term sustainable growth. We will soon reveal our comprehensive strategy that revitalizes Rite Aid retail pharmacies as fresh and relevant, leveraging the trust and expertise of our pharmacists in meeting the unique health and wellbeing needs of our communities. We are also investing in the expansion and integration of EnvisionRxOptions, particularly its services, technologies and clinical offerings. This will provide us scale to deliver lower total cost of care, an enhanced client experience and heightened consumer engagement. We are making great progress, and we are excited to share more details at our upcoming Analyst Day on March 16.”
-More-
Rite Aid FY 2020 Q3 Press Release - page 2
Third Quarter Summary
Revenues from continuing operations for the quarter were $5.46 billion compared to revenues from continuing operations of $5.45 billion in the prior year’s quarter. Retail Pharmacy Segment revenues were $3.91 billion and decreased 1.7 percent compared to the prior year period due to a reduction in store count. Revenues in the Pharmacy Services Segment were $1.61 billion, an increase of 5.7 percent compared to the prior year period, which was due to an increase in Medicare Part D membership.
Retail Pharmacy Segment same store sales from continuing operations for the third quarter decreased 0.1 percent over the prior year period, consisting of a 0.1 percent increase in pharmacy sales and a 0.5 percent decrease in front-end sales. Front-end same store sales, excluding cigarettes and tobacco products, increased 1.0 percent. Pharmacy sales were negatively impacted by approximately 331 basis points as a result of new generic introductions. The number of prescriptions filled in same stores, adjusted to 30-day equivalents, increased 2.8 percent over the prior year period resulting primarily from the company’s continued emphasis on driving clinical services, including immunizations. Prescription sales from continuing operations accounted for 67.7 percent of total drugstore sales.
Net income from continuing operations was $52.3 million or $0.98 per share compared to last year’s third quarter net loss from continuing operations of $17.3 million or $0.33 per share. The increase in net income was due primarily to a $55.7 million gain on debt retirements and an increase in Adjusted EBITDA.
Adjusted EBITDA from continuing operations was $158.1 million or 2.9 percent of revenues for the third quarter compared to last year’s third quarter Adjusted EBITDA from continuing operations of $142.8 million or 2.6 percent of revenues, an increase of $15.3 million. Retail Pharmacy Segment Adjusted EBITDA from continuing operations increased $7.4 million due to strong labor and benefits expense control. These improvements were partially offset by a reduction in gross profit and a reduction in Transition Service Agreement fee income from Walgreens Boots Alliance. The Pharmacy Services Segment Adjusted EBITDA increased $7.9 million compared to the prior year due to improvements in pharmacy network management.
Outlook for Fiscal 2020
Rite Aid Corporation is updating its fiscal 2020 outlook, which includes narrowing its guidance for Adjusted EBITDA. The company’s outlook assumes continued prescription count growth, improvements in generic drug costs and strong SG&A expense control, offset by a decline in prescription reimbursement rates. The fiscal 2020 guidance for EnvisionRxOptions assumes sustained improvements in pharmacy network management and initial results of SG&A reduction, benefits integration and restructuring initiatives.
Rite Aid Corporation expects revenues to be between $21.5 billion and $21.9 billion in fiscal 2020 with same store sales expected to range from an increase of 0.0 percent to an increase of 1.0 percent over fiscal 2019.
Net loss is expected to be between $174.0 million and $204.0 million.
Adjusted EBITDA is expected to be between $515.0 million and $545.0 million.
Adjusted net income per share is expected to be between $0.13 and $0.55.
Capital expenditures are expected to be approximately $230 million.
-More-
Rite Aid FY 2020 Q3 Press Release - page 3
Conference Call Broadcast
Rite Aid Corporation will hold an analyst call at 8:30 a.m. Eastern Time today with remarks by Rite Aid's management team. The call will be simulcast via the internet and can be accessed at www.riteaid.com in the conference call section of investor information. A playback of the call will also be available by telephone beginning at 12:00 p.m. Eastern Time today until 11:59 p.m. Eastern Time on Dec. 21, 2019. The playback number is 1-855-859-2056 from within the U.S. and Canada or 1-404-537-3406 from outside the U.S. and Canada with the reservation number 6188277.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering health care services and retail products to over 1.6 million Americans
daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array
of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 18 states.
Through EnvisionRxOptions, we also deliver pharmacy benefit management to approximately 1,900 clients and 3.4 million members.
For more information, visit www.riteaid.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Rite Aid’s outlook and guidance for fiscal 2020; Rite Aid’s competitive position and ability to realize its growth initiatives and operating efficiencies; and any assumptions underlying any of the foregoing. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” and “will” and variations of such words and similar expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, our high level of indebtedness and our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our debt agreements; general economic, industry, market, competitive, regulatory and political conditions; our ability to improve the operating performance of our stores in accordance with our long term strategy; the ongoing impact of private and public third-party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order; our ability to manage expenses and our investments in working capital; outcomes of legal and regulatory matters; changes in legislation or regulations, including healthcare reform; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; risks related to the pending sale of the remaining Rite Aid distribution center and related assets to Walgreens Boots Alliance, Inc. ("WBA"), including the possibility that the transaction may not close due to the failure to satisfy the minimal remaining conditions; our ability to successfully achieve benefits from our leadership transition plan and organizational restructuring, including managing the transition to our new chief executive officer and other management; the potential for operational disruptions due to, among other things, concerns of management, employees, current and potential customers, other third parties with whom we do business and shareholders; the success of any changes to our business strategy that may be implemented under our new chief executive officer and other management; our ability to achieve cost savings through the organizational restructurings within the anticipated timeframe, if at all; possible changes in the size and components of the expected costs and charges associated with the organizational restructuring plan; and the outlook for and future growth of the Company.
These and other risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission, which you are encouraged to read.
-More-
Rite Aid FY 2020 Q3 Press Release - page 4
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
Reconciliation of Non-GAAP Financial Measures
Rite Aid separately reports financial results on the basis of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA which are non-GAAP financial measures. See the attached tables for a reconciliation of Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Adjusted EBITDA to net income (loss), and net income (loss) per diluted share, which are the most directly comparable GAAP financial measures. Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition-related costs, non-recurring litigation settlement, gains and losses on debt retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring-related costs and the WBA merger termination fee. The current calculations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share reflect a modification made in the second quarter of fiscal 2019 to add back all amortization expenses rather than the amortization of EnvisionRx intangible assets only. Adjusted EBITDA is defined as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt retirements, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation settlement, severance, restructuring-related costs and costs related to facility closures and gain or loss on sale of assets). The current calculation of Adjusted EBITDA reflects a modification made in the second quarter of fiscal 2019 to eliminate the add back of revenue deferrals related to our customer loyalty program and to present amounts previously included within other as separate reconciling items. We further note that the add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid’s results as if the company was on a FIFO inventory basis.
In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items. The presentation includes a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure. Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock-based compensation expense, merger and acquisition-related costs, litigation settlement, restructuring-related costs and other items. The presentation includes a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure.
###
RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)
(unaudited)
November 30, 2019 | March 2, 2019 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 289,498 | $ | 144,353 | ||||
Accounts receivable, net | 1,689,838 | 1,788,712 | ||||||
Inventories, net of LIFO reserve of $611,997 and $604,444 | 1,957,045 | 1,871,941 | ||||||
Prepaid expenses and other current assets | 178,292 | 179,132 | ||||||
Current assets held for sale | 101,594 | 117,581 | ||||||
Total current assets | 4,216,267 | 4,101,719 | ||||||
Property, plant and equipment, net | 1,254,234 | 1,308,514 | ||||||
Operating lease right-of-use assets | 2,935,104 | - | ||||||
Goodwill | 1,108,136 | 1,108,136 | ||||||
Other intangibles, net | 374,660 | 448,706 | ||||||
Deferred tax assets | 382,105 | 409,084 | ||||||
Other assets | 158,285 | 215,208 | ||||||
Total assets | $ | 10,428,791 | $ | 7,591,367 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Current maturities of long-term debt and lease financing obligations | $ | 9,486 | $ | 16,111 | ||||
Accounts payable | 1,534,302 | 1,618,585 | ||||||
Accrued salaries, wages and other current liabilities | 806,739 | 808,439 | ||||||
Current portion of operating lease liabilities | 493,699 | - | ||||||
Current liabilities held for sale | 42,422 | - | ||||||
Total current liabilities | 2,886,648 | 2,443,135 | ||||||
Long-term debt, less current maturities | 3,566,261 | 3,454,585 | ||||||
Long-term operating lease liabilities | 2,732,339 | - | ||||||
Lease financing obligations, less current maturities | 20,607 | 24,064 | ||||||
Other noncurrent liabilities | 207,078 | 482,893 | ||||||
Total liabilities | 9,412,933 | 6,404,677 | ||||||
Commitments and contingencies | - | - | ||||||
Stockholders' equity: | ||||||||
Common stock | 54,862 | 54,016 | ||||||
Additional paid-in capital | 5,888,870 | 5,876,977 | ||||||
Accumulated deficit | (4,897,473 | ) | (4,713,244 | ) | ||||
Accumulated other comprehensive loss | (30,401 | ) | (31,059 | ) | ||||
Total stockholders' equity | 1,015,858 | 1,186,690 | ||||||
Total liabilities and stockholders' equity | $ | 10,428,791 | $ | 7,591,367 |
RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
Revenues | $ | 5,462,298 | $ | 5,450,060 | ||||
Costs and expenses: | ||||||||
Cost of revenues | 4,273,323 | 4,267,972 | ||||||
Selling, general and administrative expenses | 1,134,854 | 1,142,555 | ||||||
Lease termination and impairment charges | 166 | 2,628 | ||||||
Interest expense | 57,856 | 56,008 | ||||||
Gain on debt retirements, net | (55,692 | ) | - | |||||
Gain on sale of assets, net | (1,371 | ) | (382 | ) | ||||
5,409,136 | 5,468,781 | |||||||
Income (loss) from continuing operations before income taxes | 53,162 | (18,721 | ) | |||||
Income tax expense (benefit) | 876 | (1,471 | ) | |||||
Net income (loss) from continuing operations | 52,286 | (17,250 | ) | |||||
Net (loss) income from discontinued operations, net of tax | (801 | ) | 12,740 | |||||
Net income (loss) | $ | 51,485 | $ | (4,510 | ) | |||
Basic and diluted income (loss) per share: | ||||||||
Numerator for income (loss) per share: | ||||||||
Net income (loss) from continuing operations attributable to common stockholders - basic and diluted | $ | 52,286 | $ | (17,250 | ) | |||
Net (loss) income from discontinued operations attributable to common stockholders - basic and diluted | (801 | ) | 12,740 | |||||
Income (loss) attributable to common stockholders - basic and diluted | $ | 51,485 | $ | (4,510 | ) | |||
Denominator: | ||||||||
Basic weighted average shares | 53,310 | 52,920 | ||||||
Outstanding options and restricted shares, net | 274 | - | ||||||
Diluted weighted average shares | 53,584 | 52,920 | ||||||
Basic income (loss) per share | ||||||||
Continuing operations | $ | 0.98 | $ | (0.33 | ) | |||
Discontinued operations | $ | (0.01 | ) | $ | 0.24 | |||
Net basic income (loss) per share | $ | 0.97 | $ | (0.09 | ) | |||
Diluted income (loss) per share | ||||||||
Continuing operations | $ | 0.98 | $ | (0.33 | ) | |||
Discontinued operations | $ | (0.02 | ) | $ | 0.24 | |||
Net diluted income (loss) per share | $ | 0.96 | $ | (0.09 | ) |
RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
Revenues | $ | 16,201,151 | $ | 16,259,912 | ||||
Costs and expenses: | ||||||||
Cost of revenues | 12,741,014 | 12,747,924 | ||||||
Selling, general and administrative expenses | 3,433,036 | 3,449,173 | ||||||
Lease termination and impairment charges | 2,115 | 52,096 | ||||||
Goodwill and intangible asset impairment charges | - | 375,190 | ||||||
Interest expense | 176,228 | 175,033 | ||||||
(Gain) loss on debt retirements, net | (55,692 | ) | 554 | |||||
Gain on sale of assets, net | (5,670 | ) | (11,206 | ) | ||||
16,291,031 | 16,788,764 | |||||||
Loss from continuing operations before income taxes | (89,880 | ) | (528,852 | ) | ||||
Income tax expense (benefit) | 35,878 | (117,527 | ) | |||||
Net loss from continuing operations | (125,758 | ) | (411,325 | ) | ||||
Net (loss) income from discontinued operations, net of tax | (1,695 | ) | 262,091 | |||||
Net loss | $ | (127,453 | ) | $ | (149,234 | ) | ||
Basic and diluted loss per share: | ||||||||
Numerator for loss per share: | ||||||||
Net loss from continuing operations attributable to common stockholders - basic and diluted | $ | (125,758 | ) | $ | (411,325 | ) | ||
Net (loss) income from discontinued operations attributable to common stockholders - basic and diluted | (1,695 | ) | 262,091 | |||||
Loss attributable to common stockholders - basic and diluted | $ | (127,453 | ) | $ | (149,234 | ) | ||
Denominator: | ||||||||
Basic and diluted weighted average shares | 53,159 | 52,824 | ||||||
Basic and diluted loss per share | ||||||||
Continuing operations | $ | (2.37 | ) | $ | (7.79 | ) | ||
Discontinued operations | $ | (0.03 | ) | $ | 4.96 | |||
Net basic and diluted loss per share | $ | (2.40 | ) | $ | (2.83 | ) |
RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
OPERATING ACTIVITIES: | ||||||||
Net income (loss) | $ | 51,485 | $ | (4,510 | ) | |||
Net (loss) income from discontinued operations, net of tax | (801 | ) | 12,740 | |||||
Net income (loss) from continuing operations | $ | 52,286 | $ | (17,250 | ) | |||
Adjustments to reconcile to net cash provided by operating activities of continuing operations: | ||||||||
Depreciation and amortization | 82,007 | 86,685 | ||||||
Lease termination and impairment charges | 166 | 2,628 | ||||||
LIFO (credit) charge | (7,440 | ) | 5,987 | |||||
Gain on sale of assets, net | (1,371 | ) | (382 | ) | ||||
Stock-based compensation expense | 3,506 | 1,317 | ||||||
Gain on debt retirements, net | (55,692 | ) | - | |||||
Changes in deferred taxes | - | (1,295 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 252,767 | 318,287 | ||||||
Inventories | 19,333 | (46,839 | ) | |||||
Accounts payable | 47,378 | (26,446 | ) | |||||
Operating lease right-of-use assets and operating lease liabilities | (12,179 | ) | - | |||||
Other assets | 1,959 | (1,072 | ) | |||||
Other liabilities | 40,993 | 29,501 | ||||||
Net cash provided by operating activities of continuing operations | 423,713 | 351,121 | ||||||
INVESTING ACTIVITIES: | ||||||||
Payments for property, plant and equipment | (45,075 | ) | (46,653 | ) | ||||
Intangible assets acquired | (17,727 | ) | (11,054 | ) | ||||
Proceeds from dispositions of assets and investments | 51,548 | 72 | ||||||
Net cash used in investing activities of continuing operations | (11,254 | ) | (57,635 | ) | ||||
FINANCING ACTIVITIES: | ||||||||
Net payments to revolver | (115,000 | ) | (90,000 | ) | ||||
Principal payments on long-term debt | (101,251 | ) | (3,851 | ) | ||||
Change in zero balance cash accounts | (66,461 | ) | 1,137 | |||||
Net proceeds from the issuance of common stock | - | 992 | ||||||
Payments for taxes related to net share settlement of equity awards | (587 | ) | (175 | ) | ||||
Financing fees paid for early debt redemption | (518 | ) | - | |||||
Net cash used in financing activities of continuing operations | (283,817 | ) | (91,897 | ) | ||||
Cash flows from discontinued operations: | ||||||||
Operating activities of discontinued operations | (4,876 | ) | 14,735 | |||||
Investing activities of discontinued operations | 23,551 | 61,251 | ||||||
Net cash provided by discontinued operations | 18,675 | 75,986 | ||||||
Increase in cash and cash equivalents | 147,317 | 277,575 | ||||||
Cash and cash equivalents, beginning of period | 142,181 | 132,468 | ||||||
Cash and cash equivalents, end of period | $ | 289,498 | $ | 410,043 |
RITE AID CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (127,453 | ) | $ | (149,234 | ) | ||
Net (loss) income from discontinued operations, net of tax | (1,695 | ) | 262,091 | |||||
Net loss from continuing operations | $ | (125,758 | ) | $ | (411,325 | ) | ||
Adjustments to reconcile to net cash provided by operating activities of continuing operations: | ||||||||
Depreciation and amortization | 248,977 | 270,957 | ||||||
Lease termination and impairment charges | 2,115 | 52,096 | ||||||
Goodwill and intangible asset impairment charges | - | 375,190 | ||||||
LIFO charge | 7,553 | 19,311 | ||||||
Gain on sale of assets, net | (5,670 | ) | (11,206 | ) | ||||
Stock-based compensation expense | 13,598 | 11,563 | ||||||
(Gain) loss on debt retirements, net | (55,692 | ) | 554 | |||||
Changes in deferred taxes | 26,979 | (126,102 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 99,498 | (5,437 | ) | |||||
Inventories | (92,657 | ) | (78,489 | ) | ||||
Accounts payable | (38,245 | ) | 181,497 | |||||
Operating lease right-of-use assets and operating lease liabilities | 22,803 | - | ||||||
Other assets | (42,715 | ) | (12,304 | ) | ||||
Other liabilities | 32,889 | (216,086 | ) | |||||
Net cash provided by operating activities of continuing operations | 93,675 | 50,219 | ||||||
INVESTING ACTIVITIES: | ||||||||
Payments for property, plant and equipment | (129,135 | ) | (139,218 | ) | ||||
Intangible assets acquired | (33,435 | ) | (31,573 | ) | ||||
Proceeds from dispositions of assets and investments | 55,971 | 15,801 | ||||||
Proceeds from sale-leaseback transactions | - | 2,587 | ||||||
Net cash used in investing activities of continuing operations | (106,599 | ) | (152,403 | ) | ||||
FINANCING ACTIVITIES: | ||||||||
Net proceeds from revolver | 260,000 | 1,245,000 | ||||||
Principal payments on long-term debt | (104,702 | ) | (437,597 | ) | ||||
Change in zero balance cash accounts | (11,749 | ) | (15,964 | ) | ||||
Net proceeds from the issuance of common stock | - | 2,294 | ||||||
Payments for taxes related to net share settlement of equity awards | (1,573 | ) | (2,419 | ) | ||||
Financing fees paid for early debt redemption | (518 | ) | (13 | ) | ||||
Deferred financing costs paid | (315 | ) | - | |||||
Net cash provided by financing activities of continuing operations | 141,143 | 791,301 | ||||||
Cash flows from discontinued operations: | ||||||||
Operating activities of discontinued operations | (7,148 | ) | (47,268 | ) | ||||
Investing activities of discontinued operations | 24,074 | 664,653 | ||||||
Financing activities of discontinued operations | - | (1,343,793 | ) | |||||
Net cash provided by (used in) discontinued operations | 16,926 | (726,408 | ) | |||||
Increase (decrease) in cash and cash equivalents | 145,145 | (37,291 | ) | |||||
Cash and cash equivalents, beginning of period | 144,353 | 447,334 | ||||||
Cash and cash equivalents, end of period | $ | 289,498 | $ | 410,043 |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL SEGMENT OPERATING INFORMATION
(Dollars in thousands)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
Retail Pharmacy Segment | ||||||||
Revenues from continuing operations (a) | $ | 3,909,946 | $ | 3,976,719 | ||||
Cost of revenues from continuing operations (a) | 2,839,094 | 2,897,135 | ||||||
Gross profit from continuing operations | 1,070,852 | 1,079,584 | ||||||
LIFO (credit) charge from continuing operations | (7,440 | ) | 5,987 | |||||
FIFO gross profit from continuing operations | 1,063,412 | 1,085,571 | ||||||
Adjusted EBITDA gross profit from continuing operations | 1,065,523 | 1,088,213 | ||||||
Gross profit as a percentage of revenues - continuing operations | 27.39 | % | 27.15 | % | ||||
LIFO (credit) charge as a percentage of revenues - continuing operations | -0.19 | % | 0.15 | % | ||||
FIFO gross profit as a percentage of revenues - continuing operations | 27.20 | % | 27.30 | % | ||||
Adjusted EBITDA gross profit as a percentage of revenues - continuing operations | 27.25 | % | 27.36 | % | ||||
Selling, general and administrative expenses from continuing operations | 1,044,236 | 1,062,598 | ||||||
Adjusted EBITDA selling, general and administrative expenses from continuing operations | 956,944 | 986,988 | ||||||
Selling, general and administrative expenses as a percentage of revenues - continuing operations | 26.71 | % | 26.72 | % | ||||
Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues - continuing operations | 24.47 | % | 24.82 | % | ||||
Cash interest expense | 54,068 | 52,074 | ||||||
Non-cash interest expense | 3,788 | 3,934 | ||||||
Total interest expense | 57,856 | 56,008 | ||||||
Interest expense - continuing operations | 57,856 | 56,008 | ||||||
Interest expense - discontinued operations | - | - | ||||||
Adjusted EBITDA - continuing operations | 108,579 | 101,225 | ||||||
Adjusted EBITDA as a percentage of revenues - continuing operations | 2.78 | % | 2.55 | % | ||||
Pharmacy Services Segment | ||||||||
Revenues (a) | $ | 1,613,109 | $ | 1,525,837 | ||||
Cost of revenues (a) | 1,494,986 | 1,423,333 | ||||||
Gross profit | 118,123 | 102,504 | ||||||
Gross profit as a percentage of revenues | 7.32 | % | 6.72 | % | ||||
Adjusted EBITDA | 49,511 | 41,566 | ||||||
Adjusted EBITDA as a percentage of revenues | 3.07 | % | 2.72 | % |
(a) - Revenues and cost of revenues include $60,757 and $52,496 of inter-segment activity for the thirteen weeks ended November 30, 2019 and December 1, 2018, respectively, that is eliminated in consolidation.
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL SEGMENT OPERATING INFORMATION
(Dollars in thousands)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
Retail Pharmacy Segment | ||||||||
Revenues from continuing operations (a) | $ | 11,622,858 | $ | 11,785,996 | ||||
Cost of revenues from continuing operations (a) | 8,489,067 | 8,585,318 | ||||||
Gross profit from continuing operations | 3,133,791 | 3,200,678 | ||||||
LIFO charge from continuing operations | 7,553 | 19,311 | ||||||
FIFO gross profit from continuing operations | 3,141,344 | 3,219,989 | ||||||
Adjusted EBITDA gross profit from continuing operations | 3,151,043 | 3,229,993 | ||||||
Gross profit as a percentage of revenues - continuing operations | 26.96 | % | 27.16 | % | ||||
LIFO charge as a percentage of revenues - continuing operations | 0.06 | % | 0.16 | % | ||||
FIFO gross profit as a percentage of revenues - continuing operations | 27.03 | % | 27.32 | % | ||||
Adjusted EBITDA gross profit as a percentage of revenues - continuing operations | 27.11 | % | 27.41 | % | ||||
Selling, general and administrative expenses from continuing operations | 3,160,379 | 3,195,929 | ||||||
Adjusted EBITDA selling, general and administrative expenses from continuing operations | 2,865,783 | 2,921,021 | ||||||
Selling, general and administrative expenses as a percentage of revenues - continuing operations | 27.19 | % | 27.12 | % | ||||
Adjusted EBITDA selling, general and administrative expenses as a percentage of revenues - continuing operations | 24.66 | % | 24.78 | % | ||||
Cash interest expense | 164,982 | 167,270 | ||||||
Non-cash interest expense | 11,246 | 12,378 | ||||||
Total interest expense | 176,228 | 179,648 | ||||||
Interest expense - continuing operations | 176,228 | 175,033 | ||||||
Interest expense - discontinued operations | - | 4,615 | ||||||
Adjusted EBITDA - continuing operations | 285,260 | 308,972 | ||||||
Adjusted EBITDA as a percentage of revenues - continuing operations | 2.45 | % | 2.62 | % | ||||
Pharmacy Services Segment | ||||||||
Revenues (a) | $ | 4,758,470 | $ | 4,630,410 | ||||
Cost of revenues (a) | 4,432,124 | 4,319,100 | ||||||
Gross profit | 326,346 | 311,310 | ||||||
Gross profit as a percentage of revenues | 6.86 | % | 6.72 | % | ||||
Adjusted EBITDA | 117,367 | 120,392 | ||||||
Adjusted EBITDA as a percentage of revenues | 2.47 | % | 2.60 | % |
(a) - Revenues and cost of revenues include $180,177 and $156,494 of inter-segment activity for the thirty-nine weeks ended November 30, 2019 and December 1, 2018, respectively, that is eliminated in consolidation.
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
(In thousands)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
Reconciliation of net income (loss) to adjusted EBITDA: | ||||||||
Net income (loss) - continuing operations | $ | 52,286 | $ | (17,250 | ) | |||
Adjustments: | ||||||||
Interest expense | 57,856 | 56,008 | ||||||
Income tax expense (benefit) | 876 | (1,471 | ) | |||||
Depreciation and amortization | 82,007 | 86,685 | ||||||
LIFO (credit) charge | (7,440 | ) | 5,987 | |||||
Lease termination and impairment charges | 166 | 2,628 | ||||||
Gain on debt retirements, net | (55,692 | ) | - | |||||
Merger and Acquisition-related costs | - | 4,175 | ||||||
Stock-based compensation expense | 3,506 | 1,317 | ||||||
Restructuring-related costs | 25,275 | - | ||||||
Inventory write-downs related to store closings | 93 | 421 | ||||||
Gain on sale of assets, net | (1,371 | ) | (382 | ) | ||||
Other | 528 | 4,673 | ||||||
Adjusted EBITDA - continuing operations | $ | 158,090 | $ | 142,791 | ||||
Percent of revenues - continuing operations | 2.89 | % | 2.62 | % |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(In thousands)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
Reconciliation of net loss to adjusted EBITDA: | ||||||||
Net loss - continuing operations | $ | (125,758 | ) | $ | (411,325 | ) | ||
Adjustments: | ||||||||
Interest expense | 176,228 | 175,033 | ||||||
Income tax expense (benefit) | 35,878 | (117,527 | ) | |||||
Depreciation and amortization | 248,977 | 270,957 | ||||||
LIFO charge | 7,553 | 19,311 | ||||||
Lease termination and impairment charges | 2,115 | 52,096 | ||||||
Goodwill and intangible asset impairment charges | - | 375,190 | ||||||
(Gain) loss on debt retirements, net | (55,692 | ) | 554 | |||||
Merger and Acquisition-related costs | 3,599 | 30,394 | ||||||
Stock-based compensation expense | 13,598 | 11,563 | ||||||
Restructuring-related costs | 93,770 | - | ||||||
Inventory write-downs related to store closings | 4,083 | 5,554 | ||||||
Litigation settlement | - | 18,000 | ||||||
Gain on sale of assets, net | (5,670 | ) | (11,206 | ) | ||||
Other | 3,946 | 10,770 | ||||||
Adjusted EBITDA - continuing operations | $ | 402,627 | $ | 429,364 | ||||
Percent of revenues - continuing operations | 2.49 | % | 2.64 | % |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
ADJUSTED NET INCOME
(Dollars in thousands, except per share amounts)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
Net income (loss) from continuing operations | $ | 52,286 | $ | (17,250 | ) | |||
Add back - Income tax expense (benefit) | 876 | (1,471 | ) | |||||
Income (loss) before income taxes - continuing operations | 53,162 | (18,721 | ) | |||||
Adjustments: | ||||||||
Amortization expense | 24,920 | 28,768 | ||||||
LIFO (credit) charge | (7,440 | ) | 5,987 | |||||
Gain on debt retirements, net | (55,692 | ) | - | |||||
Merger and Acquisition-related costs | - | 4,175 | ||||||
Restructuring-related costs | 25,275 | - | ||||||
Adjusted income before income taxes - continuing operations | 40,225 | 20,209 | ||||||
Adjusted income tax expense (a) | 11,090 | 5,469 | ||||||
Adjusted net income from continuing operations | $ | 29,135 | $ | 14,740 | ||||
Adjusted net income per diluted share - continuing operations: | ||||||||
Numerator for adjusted net income per diluted share: | ||||||||
Adjusted net income from continuing operations | $ | 29,135 | $ | 14,740 | ||||
Denominator: | ||||||||
Basic weighted average shares | 53,310 | 52,920 | ||||||
Outstanding options and restricted shares, net | 274 | 10 | ||||||
Diluted weighted average shares | 53,584 | 52,930 | ||||||
Net income (loss) from continuing operations per diluted share - continuing operations | $ | 0.98 | $ | (0.33 | ) | |||
Adjusted net income per diluted share - continuing operations | $ | 0.54 | $ | 0.28 |
(a) The fiscal year 2020 and 2019 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen weeks ended November 30, 2019 and December 1, 2018, respectively.
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
ADJUSTED NET INCOME
(Dollars in thousands, except per share amounts)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
Net loss from continuing operations | $ | (125,758 | ) | $ | (411,325 | ) | ||
Add back - Income tax expense (benefit) | 35,878 | (117,527 | ) | |||||
Loss before income taxes - continuing operations | (89,880 | ) | (528,852 | ) | ||||
Adjustments: | ||||||||
Amortization expense | 79,176 | 96,668 | ||||||
LIFO charge | 7,553 | 19,311 | ||||||
Goodwill and intangible asset impairment charges | - | 375,190 | ||||||
(Gain) loss on debt retirements, net | (55,692 | ) | 554 | |||||
Merger and Acquisition-related costs | 3,599 | 30,394 | ||||||
Restructuring-related costs | 93,770 | - | ||||||
Litigation settlement | - | 18,000 | ||||||
Adjusted income before income taxes - continuing operations | 38,526 | 11,265 | ||||||
Adjusted income tax expense (a) | 10,622 | 3,049 | ||||||
Adjusted net income from continuing operations | $ | 27,904 | $ | 8,216 | ||||
Adjusted net income per diluted share - continuing operations: | ||||||||
Numerator for adjusted net income per diluted share: | ||||||||
Adjusted net income from continuing operations | $ | 27,904 | $ | 8,216 | ||||
Denominator: | ||||||||
Basic weighted average shares | 53,159 | 52,824 | ||||||
Outstanding options and restricted shares, net | 775 | 124 | ||||||
Diluted weighted average shares | 53,934 | 52,948 | ||||||
Net loss from continuing operations per diluted share - continuing operations | $ | (2.37 | ) | $ | (7.79 | ) | ||
Adjusted net income diluted share - continuing operations | $ | 0.52 | $ | 0.16 |
(a) The fiscal year 2020 and 2019 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirty-nine weeks ended November 30, 2019 and December 1, 2018, respectively.
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT
(In thousands)
(unaudited)
Thirteen weeks ended November 30, 2019 | Thirteen weeks ended December 1, 2018 | |||||||
Reconciliation of adjusted EBITDA gross profit: | ||||||||
Revenues | $ | 3,909,946 | $ | 3,976,719 | ||||
Gross Profit | 1,070,852 | 1,079,584 | ||||||
Addback: | ||||||||
LIFO (credit) charge | (7,440 | ) | 5,987 | |||||
Depreciation and amortization (cost of goods sold portion only) | 2,070 | 2,308 | ||||||
Other | 41 | 334 | ||||||
Adjusted EBITDA gross profit - continuing operations | $ | 1,065,523 | $ | 1,088,213 | ||||
Percent of revenues - continuing operations | 27.25 | % | 27.36 | % | ||||
Reconciliation of adjusted EBITDA selling, general and administrative expenses: | ||||||||
Revenues | $ | 3,909,946 | $ | 3,976,719 | ||||
Selling, general and administrative expenses | 1,044,236 | 1,062,598 | ||||||
Less: | ||||||||
Depreciation and amortization (SG&A portion only) | 65,267 | 67,905 | ||||||
Stock-based compensation expense | 2,976 | 1,317 | ||||||
Merger and Acquisition-related costs | - | 4,175 | ||||||
Restructuring-related costs | 18,415 | - | ||||||
Other | 634 | 2,213 | ||||||
Adjusted EBITDA selling, general and administrative expenses - continuing operations | $ | 956,944 | $ | 986,988 | ||||
Percent of revenues - continuing operations | 24.47 | % | 24.82 | % | ||||
Adjusted EBITDA - continuing operations | $ | 108,579 | $ | 101,225 |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF ADJUSTED EBITDA GROSS PROFIT AND RECONCILIATION OF ADJUSTED EBITDA SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES- RETAIL PHARMACY SEGMENT
(In thousands)
(unaudited)
Thirty-nine weeks ended November 30, 2019 | Thirty-nine weeks ended December 1, 2018 | |||||||
Reconciliation of adjusted EBITDA gross profit: | ||||||||
Revenues | $ | 11,622,858 | $ | 11,785,996 | ||||
Gross Profit | 3,133,791 | 3,200,678 | ||||||
Addback: | ||||||||
LIFO charge | 7,553 | 19,311 | ||||||
Depreciation and amortization (cost of goods sold portion only) | 6,538 | 6,929 | ||||||
Other | 3,161 | 3,075 | ||||||
Adjusted EBITDA gross profit - continuing operations | $ | 3,151,043 | $ | 3,229,993 | ||||
Percent of revenues - continuing operations | 27.11 | % | 27.41 | % | ||||
Reconciliation of adjusted EBITDA selling, general and administrative expenses: | ||||||||
Revenues | $ | 11,622,858 | $ | 11,785,996 | ||||
Selling, general and administrative expenses | 3,160,379 | 3,195,929 | ||||||
Less: | ||||||||
Depreciation and amortization (SG&A portion only) | 195,281 | 205,972 | ||||||
Stock-based compensation expense | 12,673 | 11,563 | ||||||
Merger and Acquisition-related costs | 2,828 | 30,394 | ||||||
Restructuring-related costs | 78,851 | - | ||||||
Litigation settlement | - | 18,000 | ||||||
Other | 4,963 | 8,979 | ||||||
Adjusted EBITDA selling, general and administrative expenses - continuing operations | $ | 2,865,783 | $ | 2,921,021 | ||||
Percent of revenues - continuing operations | 24.66 | % | 24.78 | % | ||||
Adjusted EBITDA - continuing operations | $ | 285,260 | $ | 308,972 |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE
YEAR ENDING FEBRUARY 29, 2020
(In thousands)
(unaudited)
Guidance Range | ||||||||
Low | High | |||||||
Total Revenues | $ | 21,500,000 | $ | 21,900,000 | ||||
Same store sales | 0.00 | % | 1.00 | % | ||||
Gross Capital Expenditures | $ | 230,000 | $ | 230,000 | ||||
Reconciliation of net loss to adjusted EBITDA: | ||||||||
Net loss | $ | (204,000 | ) | $ | (174,000 | ) | ||
Adjustments: | ||||||||
Interest expense | 235,000 | 235,000 | ||||||
Income tax expense | 40,000 | 40,000 | ||||||
Depreciation and amortization | 330,000 | 330,000 | ||||||
LIFO charge | 10,000 | 10,000 | ||||||
Lease termination and impairment charges | 35,000 | 35,000 | ||||||
Gain on debt retirements, net | (56,000 | ) | (56,000 | ) | ||||
Restructuring-related costs | 100,000 | 100,000 | ||||||
Other | 25,000 | 25,000 | ||||||
Adjusted EBITDA | $ | 515,000 | $ | 545,000 |
RITE AID CORPORATION AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED NET INCOME GUIDANCE
YEAR ENDING FEBRUARY 29, 2020
(In thousands)
(unaudited)
Guidance Range | ||||||||
Low | High | |||||||
Net loss | $ | (204,000 | ) | $ | (174,000 | ) | ||
Add back - income tax expense | 40,000 | 40,000 | ||||||
Loss before income taxes | (164,000 | ) | (134,000 | ) | ||||
Adjustments: | ||||||||
Amortization expense | 120,000 | 120,000 | ||||||
LIFO charge | 10,000 | 10,000 | ||||||
Gain on debt retirements, net | (56,000 | ) | (56,000 | ) | ||||
Restructuring-related costs | 100,000 | 100,000 | ||||||
Adjusted income before adjusted income taxes | 10,000 | 40,000 | ||||||
Adjusted income tax expense | 3,000 | 11,000 | ||||||
Adjusted net income | $ | 7,000 | $ | 29,000 | ||||
Diluted adjusted net income per share | $ | 0.13 | $ | 0.55 |
Exhibit 99.2
a December 19, 2019 Supplemental Presentation Third Quarter Fiscal 2020
Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical, are forward - looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such statements include, but are not limited to, statements regarding Rite Aid’s outlook and guidance for fiscal 2020 ; the expected timing and the ability to complete the subsequent closings of the sale of the remaining Rite Aid distribution center and related assets to Walgreens Boots Alliance, Inc . ("WBA") ; Rite Aid’s competitive position and ability to implement new strategies following completion of such transaction with WBA ; and any assumptions underlying any of the foregoing . Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” and “will” and variations of such words and similar expressions are intended to identify such forward - looking statements . These forward - looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, our high level of indebtedness and our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our debt agreements ; general economic, industry, market, competitive, regulatory and political conditions ; our ability to improve the operating performance of our stores in accordance with our long term strategy ; the ongoing impact of private and public third - party payers continued reduction in prescription drug reimbursements and efforts to encourage mail order ; our ability to manage expenses and our investments in working capital ; outcomes of legal and regulatory matters ; changes in legislation or regulations, including healthcare reform ; our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs ; risks related to the pending sale of the remaining Rite Aid distribution center and related assets to WBA, including the possibility that the transaction may not close due to the failure to satisfy the minimal remaining conditions ; our ability to successfully achieve benefits from our leadership transition plan and organizational restructuring, including managing the transition to our new chief executive officer and other management ; the potential for operational disruptions due to, among other things, concerns of management, employees, current and potential customers, other third parties with whom we do business and shareholders ; the success of any changes to our business strategy that may be implemented under our new chief executive officer and other management ; our ability to achieve cost savings through the organizational restructurings within the anticipated timeframe, if at all ; possible changes in the size and components of the expected costs and charges associated with the organizational restructuring plan ; and the outlook for and future growth of the Company . These and other risks, assumptions and uncertainties are more fully described in Item 1 A (Risk Factors) of our most recent Annual Report on Form 10 - K and in other documents that we file or furnish with the Securities and Exchange Commission (the “SEC”), which you are encouraged to read . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward - looking statements . Accordingly, you are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date they are made . Rite Aid expressly disclaims any current intention to update publicly any forward - looking statement after the distribution of this presentation, whether as a result of new information, future events, changes in assumptions or otherwise . Safe Harbor Statement
Cautionary Note Regarding Pro Forma Information The following presentation provides certain pro forma information regarding the impact of Rite Aid’s pending sale of a distribution center and assets to WBA on Rite Aid’s results of operations and capital structure . The pro forma information is for illustrative purposes only, was prepared by management in response to investor inquiries and is based upon a number of assumptions . The pro forma information assumes the completion of all the asset sales when they actually take place over an extended period of time . Additional items that may require adjustments to the pro forma information may be identified and could result in material changes to the information contained herein . The information in this presentation is not necessarily indicative of what actual financial results of Rite Aid would have been had the sale occurred on the dates or for the periods indicated, nor does it purport to project the financial results of Rite Aid for any future periods or as of any date . Such pro forma information has not been prepared in conformity with Regulation S - X . Rite Aid’s independent auditors have not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial information . Accordingly, they do not express an opinion or provide any form of assurance with respect thereto . The information in this presentation should not be viewed in replacement of results prepared in compliance with Generally Accepted Accounting Principles or any pro forma financial statements subsequently required by the rules and regulations of the SEC . Safe Harbor Statement (cont.)
The following presentation includes the non - GAAP financial measures, Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share, Adjusted EBITDA Gross Profit and Adjusted EBITDA SG&A . Rite Aid defines Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write - downs related to store closings , gains or losses on debt retirements, the WBA merger termination fee, and other items (including stock - based compensation expense, merger and acquisition - related costs, a non - recurring litigation settlement, severance, restructuring - related costs and costs related to facility closures and gain or loss on sale of assets) . The current calculation of Adjusted EBITDA reflects a modification made in the third quarter of fiscal 2019 to eliminate the add back of revenue deferrals related to our customer loyalty program and to present amounts previously included within other as separate reconciling items . The presentation includes a reconciliation of Adjusted EBITDA to net income (loss), which is the most directly comparable GAAP financial measure . Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share exclude amortization expense, merger and acquisition - related costs, a non - recurring litigation settlement , gains or losses on debt retirements, LIFO adjustments, goodwill and intangible asset impairment charges, restructuring - related costs and the WBA merger termination fee . The current calculations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share reflect a modification made in the third quarter of fiscal 2019 to add back all amortization expenses rather than the amortization of EnvisionRx intangible assets only . Additionally, the add back of LIFO (credit) charge when calculating Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share removes the entire impact of LIFO (credits) charges, and effectively reflects Rite Aid’s results as if the company was on a FIFO inventory basis . The presentation includes a reconciliation of Adjusted Net Income (Loss) to net income (loss), which is the most directly comparable GAAP financial measure . Adjusted EBITDA Gross Profit includes LIFO adjustments, depreciation and amortization (COGS portion only) and other items . The presentation includes a reconciliation of Adjusted EBITDA Gross Profit to Revenue, which is the most directly comparable GAAP financial measure . Adjusted EBITDA SG&A excludes depreciation and amortization (SG&A portion only), stock - based compensation expense, merger and acquisition - related costs, litigation settlement and other items . The presentation includes a reconciliation of Adjusted EBITDA SG&A to Revenue, which is the most directly comparable GAAP financial measure . Non - GAAP Financial Measures
Third Quarter Adjusted EBITDA of $158.1 million exceeded prior year by $15.3 million Retail Pharmacy: • Same store 30 - day equivalent prescription count grew 2.8% • Front end sales increase 1.0% excluding tobacco related products • Strong expense control EnvisionRx : • Medicare Part D membership continues to drive revenues • Improved pharmacy network management Impr oved pharmacy network performance Continued financial improvement: • Strong free cash flow due to the receipt of the CMS receivable • Our leverage ratio decreased from 6.8 in the prior quarter to 5.9 EnvisonRx • Strong commercial selling season having won over 300,000 new lives Key Third Quarter FY 2020 Highlights 5
Q3 Fiscal 2020 Summary ($ in millions, except per share amounts) Note: Data on this slide and throughout the presentation is on a continuing operations basis. 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1 , 2018 Revenue $ 5,462.3 $ 5,450.1 Net Income (Loss) $ 52.3 $ (17.3) Net Income (Loss) per Diluted Share $ 0.98 $ (0.33) Adjusted Net Income per Diluted Share $ 0.54 $ 0.28 Adjusted EBITDA $ 158.1 2.89% $ 142.8 2.62%
Q3 - Fiscal 2020 Reconciliation of Net Income (Loss) to Adjusted EBITDA 7 ($ in thousands) 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1, 2018 Net Income (Loss) $ 52,286 $ (17,250) Adjustments: Interest expense 57,856 56,008 Income tax expense (benefit) 876 ( 1,471) Depreciation and amortization 82,007 86,685 LIFO (credit) charge (7,440) 5,987 Lease termination and impairment charges 166 2,628 Gain on debt retirement, net (55,692) - Merger and Acquisition - related costs - 4,175 Stock - based compensation expense 3,506 1,317 Restructuring - related costs 25,275 - Inventory write - downs related to store closings 93 421 Gain on sale of assets, net (1,371) (382) Other 528 4,673 Adjusted EBITDA $ 158,090 $ 142,791 Percent of revenues 2.89% 2.62%
Q3 - Fiscal 2020 Reconciliation of Net Income (Loss) to Adjusted Net Income ($ in thousands, except per share amounts) 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1 , 2018 Net Income (Loss) $ 52,286 $ (17,250) Add back - Income tax expense (benefit) 876 (1,471) Income (loss) before income taxes $ 53,162 $ (18,721) Adjustments: Amortization expense 24,920 28,768 LIFO (credit) charge (7,440) 5,987 Gain on debt retirement, net (55,692) - Merger and Acquisition - related costs - 4,175 Restructuring - related costs 25,275 - Adjusted income before income taxes $ 40,225 $ 20,209 Adjusted income tax expense 11,090 5,469 Adjusted net income $ 29,135 $ 14,740 Net income (loss) per diluted share $ 0.98 $ (0.33) Adjusted net income per diluted share $ 0.54 $ 0.28
Q3 - Fiscal 2020 Summary – Retail Pharmacy Segment 9 ($ in millions) (1) Refer to slides 11 and 12 for the reconciliations of these non - GAAP measures to their applicable GAAP measures. 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1 , 2018 Revenue $ 3,909.9 $ 3,976.7 Adjusted EBITDA Gross Profit (1) $ 1,065.5 27.25% $ 1,088.2 27.36% Adjusted EBITDA SG&A (1) $ 956.9 24.47% $ 987.0 24.82% Adjusted EBITDA $ 108.6 2.78% $ 101.2 2.55 %
• Retail Pharmacy Segment revenue decreased $66.8 million primarily driven by the 62 stores we closed since last year’s third quarter. Same store sales decreased 0.1%. Front end same store sales were down 0.5%, but up 1.0% when excluding cigarette and tobacco sales. This was partially offset by a 2.8% increase in same store prescription count. The script count increase was driven by the success of our clinical initiatives and immunization program. • Adjusted EBITDA Gross Profit decreased $22.7 million and Adjusted EBITDA Gross Margin decreased by 11 bps. Adjusted EBITDA gross profit decreased primarily due to increases in markdown dollars dues to weak summer and seasonal sell - through, lower vendor promotional funding, and a reimbursement rate adjustment resulting from the finalization of a contract with one of our payors . • Adjusted EBITDA SG&A was $30.1 million better than the prior year. Adjusted EBITDA SG&A was favorably impacted by decreases in store and corporate salaries and benefits, partially offset by lower TSA fee income from WBA. Q3 - Fiscal 2020 Summary – Retail Pharmacy Segment 10
Reconciliation of Adj. EBITDA Gross Profit – Retail Pharmacy Segment 11 ($ in millions) 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1 , 2018 Revenues $ 3,909.9 $ 3,976.7 Gross Profit 1,070.9 1,079.6 Addback: LIFO (credit) charge (7.4) 6.0 Depreciation and amortization (COGS portion only) 2.1 2.3 Other (0.1) 0.3 Adjusted EBITDA Gross Profit $ 1,065.5 $ 1,088.2 Adjusted EBITDA Gross Profit as a percent of revenue 27.25% 27.36%
Reconciliation of Adj. EBITDA SG&A - Retail Pharmacy Segment 12 ($ in millions) 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1, 2018 Revenues $ 3,909.9 $ 3,976.7 Selling, general and administrative expenses 1,044.2 1,062.6 Less: Depreciation and amortization (SG&A portion only) 65.3 67.9 Stock - based compensation expense 3.0 1.3 Merger and Acquisition - related costs - 4.2 Restructuring - related costs 18.4 - Other 0.6 2.2 Adjusted EBITDA SG&A $ 956.9 $ 987.0 Adjusted EBITDA SG&A as a percent of revenue 24.47% 24.82%
Pharmacy Services Segment Results 13 ($ in millions) 13 Weeks Ended November 30, 2019 13 Weeks Ended December 1, 2018 Revenues 1,613.1$ 1,525.8$ Cost of Revenues 1,495.0 1,423.3 Gross Profit 118.1 102.5 Selling, General and Administrative Expenses (90.6) (80.0) Loss on sale of assets, net (0.5) - Addback: Depreciation and Amortization 14.7 16.5 Loss on sale of assets, net 0.5 - Restructuring-related costs 6.9 - Other 0.4 2.6 Adjusted EBITDA - Pharmacy Services Segment 49.5$ 41.6$
• Revenues increased $87.3 million due to an increase in our Medicare Part D membership. • Adjusted EBITDA increased $7.9 million year - over - year. Pharmacy Services Segment adjusted EBITDA benefited from improvements in pharmacy network management and increased Medicare Part D membership, that were partially offset by the increases in SG&A expenses associated with the growth in Medicare Part D membership. Q3 - FY 2020 Summary – Pharmacy Services Segment 14
- 3.5% - 2.3% - 0.1% 1.6% 3.1% 2.1% 2.3% 1.5% 0.1% FRONT END SALES RX SALES Comparable Store Sales Growth SCRIPT COUNT (1) (1) Script count growth shown on a 30 - day equivalent basis. - 0.5% - 0.6% - 1.8% - 0.1% - 1.5% - 1.9% - 0.3% - 1.8% - 0.5% 0.3% - 0.6% 1.0% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 - 2.4% - 1.8% - 1.5% 1.1% 2.4% 0.8% 3.7% 2.7% 2.8% FY 2018 FY 2019 FY 2020 Excluding cigarette and tobacco products
Capitalization Table ($ in thousands) Note: Debt in the capitalization table is shown net of unamortized debt issuance costs. November 30, 2019 March 2, 2019 Secured Debt: Senior secured revolving credit facility due December 2023 $ 1,114,567 $ 850,931 FILO term loan due December 2023 446,750 446,082 1,561,317 1,297,013 Unsecured Guaranteed Debt: 6.125% senior secured notes due April 2023 1,739,633 1,736,508 1,739,663 1,736,508 Unsecured Unguaranteed Debt: 7.7% notes due February 2027 236,444 293,705 6.875% fixed - rate senior notes due December 2028 28,867 127,358 265,311 421,063 Lease financing obligations 30,093 40,176 Total Debt: 3,596,354 3,494,760 Currend maturities of long - term debt and lease fiancing obligations (9,486) (16,111) Long - term debt & lease financing obligations, less current maturities 3,586,868 3,478,649 Total debt and lease financing obligations, continuing operations Less: current maturities of long - term debt and lease financing obligations , continuing operations 3,596,354 3,494,760 Long - term debt & lease financing obligations, less current maturities, continuing operations (9,486) (16,111) $ 3,586,868 $ 3,478,649 Total Debt gross 3,634,970 3,541,666 Less: Unamortized debt issue costs (38,616) (46,906) Total Debt per balance sheet $ 3,596,354 $ 3,494,760
Pro Forma Leverage Ratio ($ in thousands) November 30, 2019 Total Debt: $ 3,596,354 Less: Cash and cash equivalents (289,498) Less: Distribution center sale proceeds (133,521) Pro Forma Net Debt $ 3,173,335 LTM Adjusted EBITDA: Retail Pharmacy Segment 381,493 Pharmacy Services Segment 155,214 LTM Adjusted EBITDA $ 536,707 Pro Forma Leverage Ratio 5.91
FY 2020 Guidance ($ in thousands) Guidance Range Low High Total Revenues $ 21,500,000 $ 21,900,000 Same store sales 0.00% 1.00% Gross Capital Expenditures $ 230,000 $ 230,000 Reconciliation of net loss to adjusted EBITDA: Net loss $ (204,000 ) $ (174,000 ) Adjustments: Interest expense 235,000 235,000 Income tax expense 40,000 40,000 Depreciation and amortization 330,000 330,000 LIFO charge 10,000 10,000 Lease termination and impairment charges 35,000 35,000 Gain on debt retirements, net (56,000) (56,000) Restructuring - related costs 100,000 100,000 Other 25,000 25,000 Adjusted EBITDA $ 515,000 $ 545,000
FY 2020 Guidance (cont.) ($ in thousands, except per share amounts) Guidance Range Low High Net loss $(204,000) $(174,000 ) Add back - income tax expense 40,000 40,000 Loss before income taxes (164,000 ) (134,000 ) Adjustments: Amortization expense 120,000 120,000 LIFO charge 10,000 10,000 Gain on debit retirements, net (56,000) (56,000) Restructuring - related costs 100,000 100,000 Adjusted income before adjusted income taxes 10,000 40,000 Adjusted income tax expense 3,000 11,000 Adjusted net income $ 7,000 $ 29,000 Diluted adjusted net income per share $ 0.13 $ 0.55
a
'CWZNYF?1X35$RXMC.1THR"X7E_HXT]M8F(BE.EZ>5
M=-4Q52I)K,3&U-9=I6NXY#\ SJ:9\Q'4'.'ITYAZ-UXK1,S$1.CZ>6M1Z(F1
M,*950IJ3&AZ>6MY>JI,1!,54UT(F)@FJF4D*TS( 6_9!8_,MUSRQ,1(-
MS^+[_6/QOU?537Y:>O>5NM[S:+Z=;;&S[ ;-(U._89U5-$U7^4@&+9M>4L647.S:JY^I-Y8UF@JA%=%0,SN5W=$<\&
MTYMQ7I99*7&QTH.-Y?\ 4=KI1%X)^>M&T=?M"4YB?4$8D:VMO0E"02E9)S"
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M./CCCXXX^../CCCXXX^../CCCXXX^../CCCXXX^../CCCXX_* CA@9 @:#6HWZZ:]OH!D D9 &H&Y6*F*^6O%%@J*TW:5BD&@%=
MSSWJQIT1-3+4JT7)B9EY1E%5..ONMM #=S4H1>/5PN%8:EM-3GIP^@$8+-3K
M]5BFU4XO RA)]UKA.\#%X/RCKR3N)F[\C+V*SF->=49R8(.C:J"6D'M:YP4I
M%LWGO%>!S7+7MF=GSGM)I]Q;0W=HS4-I[R(SW-J=W>[V_%>WQ4!/:]#+:#>J
M.W0:(GE*M"7MZWGR%^ETR).SD.I#K,N&9A#;[A940A2C7.M=)-*TH Q:L\U9
MR9J6M!KF92S-2DDF5G+/?-%LJUY(&UJ*%%35%R5/ZC4Q7TI^?5C#TKIB]Z4]GS>+=B]Z4ZL&*\ZD9HK[%>&[P0#7JJ
M^GH>?Z<,5]*?G%?2GYP#SJ=77=B\/0>PX[9@&+WI3V*L5BOZQ>W/3A@'\?9\
M=S@@'J[W/.]%[V*I$5-1F]*]6/3QP3^'/'IX^H,5]/0=3R_C ].#V+3WN7V0
M?K.'H8&?@\OZ@,_!Y?8!%>=MP-,=_P!BO#=X(!KU?!!YU?2GY]1Z9HKU&&WX
MX"J?^X"J_P#OV-/+['6*Q7TPY>IJ=%(Q]/PV_P 8?F69=I3C[S